Gene signature in melanoma associated with clinical activity a potential clue to unlock cancer immunotherapy

Cancer Journal

Volumn 16, Issue 4, 2010, Pages 399-403

  Gajewski, Thomas F ^a   Louahed, Jamila ^b   Brichard, Vincent G ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Biomarkers; Gene array; Melanoma

Indexed keywords

CANCER VACCINE;

CANCER IMMUNOTHERAPY; DNA POLYMORPHISM; GENE EXPRESSION PROFILING; MELANOMA; METASTASIS; PRIORITY JOURNAL; REVIEW; TUMOR MICROENVIRONMENT; TUMOR RESISTANCE;

ANIMALS; CANCER VACCINES; GENE EXPRESSION PROFILING; HUMANS; IMMUNITY; IMMUNOTHERAPY; MELANOMA; VACCINES, SUBUNIT;

EID: 77958012775     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e3181eacbd8     Document Type: Review

References (30)

1. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17:2105-2116.
2. Richards JM, Gilewski TA, Ramming K, et al. Effective chemotherapy for melanoma after treatment with interleukin-2. Cancer. 1992;69:427-429.
3. Weigelt B, Baehner FL, Reis-Filho JS. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J Pathol. 220:263-280.
4. Weigelt B, Hu Z, He X, et al. Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res. 2005;65:9155-9158.
5. Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359:2313-2323.
6. Harlin H, Meng Y, Peterson AC, et al. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res. 2009;69:3077-3085.
7. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960-1964.
8. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348:203-213.
9. Gajewski TF, Meng Y, Harlin H. Chemokines expressed in melanoma metastases associated with T cell infiltration. J Clin Oncol. 2007 ASCO Annual Meeting Proceedings Part I; 25 (18 S): 8501.
10. Gajewski TF, Zha Y, Thurner B, et al. Association of gene expression profile in melanoma and survival to a dendritic cell-based vaccine. J Clin Oncol. 2009;27(15 S): 9002.
11. Louahed J, Gruselle O, Gaulis S, et al. Expression of defined genes identified by pre-treatment tumor profiling: association with clinical responses to the GSK MAGE-A3 immunotherapeutic in metastatic melanoma patients. J Clin Oncol. 2008;26(suppl): Abstract 9045.
12. Hildner K, Edelson BT, Purtha WE, et al. Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science. 2008;322:1097-1100.
13. Harlin H, Kuna TV, Peterson AC, et al. Tumor progression despite massive influx of activated CD8 (+) T cells in a patient with malignant melanoma ascites. Cancer Immunol Immunother. 2006;55:1185-1197.
14. Mortarini R, Piris A, Maurichi A, et al. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. Cancer Res. 2003;63:2535-2545.
15. Gajewski TF, Meng Y, Blank C, et al. Immune resistance orchestrated by the tumor microenvironment. Immunol Rev. 2006;213:131-145. (Pubitemid 44401498)
16. Gajewski TF. Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res. 2007;13(18 Pt 1):5256-5261.
17. Mellor AL, Sivakumar J, Chandler P, et al. Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy. Nat Immunol. 2001;2:64-68.
18. Dong H, Chen L. B7-H1 pathway and its role in the evasion of tumor immunity. JMol Med. 2003;81:281-287.
19. Nomura T, Sakaguchi S. Naturally arising CD25 + CD4+ regulatory T cells in tumor immunity. Curr Top Microbiol Immunol. 2005;293:287-302.
20. Schwartz RH. T cell clonal anergy. Curr Opin Immunol. 1997;9:351-357.
21. Kline J, Brown IE, Zha YY, et al. Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma. Clin Cancer Res. 2008;14:3156-3167.
22. Brown IE, Blank C, Kline J, et al. Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejection. J Immunol. 2006;177:4521-4529.
23. Blank C, Brown I, Peterson AC, et al. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res. 2004;64:1140-1145.
24. Uyttenhove C, Pilotte L, Theate I, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2, 3-dioxygenase. Nat Med. 2003;9:1269-1274.
25. Zhang L, Gajewski TF, Kline J. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood. 2009;114:1545-1552.
26. Vansteenkiste JF, Zielinski M, Dahabreh IJ, et al. Association of gene expression signature and clinical efficacy of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) as adjuvant therapy in resected stage IB/II non-small cell lung cancer (NSCLC). J Clin Oncol. 2008;26(suppl): Abstract 7501.
27. Sullivan RJ, Hoshida Y, Brunet J, et al. A single center experience with high-dose IL-2 treatment for patients with advanced melanoma and pilot investigation of a novel gene expression signature as a predictor of response. J Clin Oncol. 2009;27(15 S): Abstract 9003.
28. Hamid O, Chasalow SD, Tsuchihashi Z, et al. Association of baseline and on-study tumor biopsy markers with clinical activity in patients with advanced melanoma treated with ipilimumab. J Clin Oncol. 2009;27(15 S): Abstract 9008.
29. Smalley KS, Flaherty KT. Development of a novel chemical class of BRAF inhibitors offers new hope for melanoma treatment. Future Oncol. 2009;5:775-778.
30. Jiang X, Zhou J, Yuen NK, et al. Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin Cancer Res. 2008;14:7726-7732.